SCHEMBL2232069

SCHEMBL2232069

CC(C)c1ccc(CS(=O)(=O)Cl)c(C(C)C)c1C(C)C

nearest known ligand 0.32

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
FABP3 P05413 1/20 0.31
FABP4 P15090 1/20 0.31
FABP5 Q01469 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9063441 0.77 ACE2 (0.34)
SCHEMBL11554595 0.75 SMN1; SMN2 (0.31)
SCHEMBL22013194 0.72 AOC1 (0.32)
SCHEMBL216708 0.72 TRPV4 (0.38)
SCHEMBL30010765 0.72 TRPV4 (0.38)
SCHEMBL3250855 0.71 GABRA1 (0.30)
SCHEMBL28186285 0.71 ACE2 (0.44)
SCHEMBL1292825 0.71 GABRA1 (0.41)
SCHEMBL3249692 0.70 ACE2 (0.31)
SCHEMBL840511 0.69 ACE2 (0.36)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10806746-B2 Di- and tri-cationic glycosylated antitumor ether lipids, L-gucosylated gaels and rhamnose-linked gaels as cytotoxic agents against epithelial cancer cells and cancer stem cells THE UNIV OF MANITOBA (CA) 2020-10-20 US disclosed
US-20170189438-A1 DI- and Tri-Cationic Glycosylated Antitumor Ether Lipids, L-Gucosylated Gaels and Rhamnose-Linked Gaels as Cytotoxic Agents Against Epithelial Cancer Cells and Cancer Stem Cells THE UNIV OF MANITOBA (CA) 2017-07-06 US disclosed
WO-2015179983-A1 DI- AND TRI-CATIONIC GLYCOSYLATED ANTITUMOR ETHER LIPIDS, L-GUCOSYLATED GAELS AND RHAMNOSE-LINKED GAELS AS CYTOTOXIC AGENTS AGAINST EPITHELIAL CANCER CELLS AND CANCER STEM CELLS THE UNIVERSITY OF MANITOBA (CA) 2015-12-03 WO disclosed
US-9169283-B2 Post-synthetic modification of nucleic acids by inverse diels-alder reaction DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) 2015-10-27 US disclosed
US-20130085271-A1 POST-SYNTHETIC MODIFICATION OF NUCLEIC ACIDS BY INVERSE DIELS-ALDER REACTION DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) 2013-04-04 US disclosed
EP-2531514-A2 POST-SYNTHETIC MODIFICATION OF NUCLEIC ACIDS BY INVERSE DIELS-ALDER REACTION Deutsches Krebsforschungszentrum (DE) 2012-12-12 EP disclosed
EP-2360167-A1 Post-synthetic modification of nucleic acids by inverse Diels-Alder reaction Deutsches Krebsforschungszentrum (DE) 2011-08-24 EP disclosed
WO-2011095336-A2 POST-SYNTHETIC MODIFICATION OF NUCLEIC ACIDS BY INVERSE DIELS-ALDER REACTION DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) 2011-08-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130085271-A1 POST-SYNTHETIC MODIFICATION OF NUCLEIC ACIDS BY INVERSE DIELS-ALDER REACTION DERA, ADAR, POLRMT FABP3 3553/4885FABP4 3043/4885FABP5 3109/4885
US-20170189438-A1 DI- and Tri-Cationic Glycosylated Antitumor Ether Lipids, L-Gucosylated Gaels and Rhamnose-Linked Gaels as Cytotoxic Agents Against Epithelial Cancer Cells and Cancer Stem Cells UGCG, PNLIP, B3GAT3 FABP3 893/4885FABP4 288/4885FABP5 1596/4885
US-10806746-B2 Di- and tri-cationic glycosylated antitumor ether lipids, L-gucosylated gaels and rhamnose-linked gaels as cytotoxic agents against epithelial cancer cells and cancer stem cells PNLIP, UGCG, LIPC FABP3 816/4885FABP4 223/4885FABP5 1613/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.